$OPK
OPKO Health Announces Positive Top-Line Results of Phase 3 Efficacy and Safety Study of Somatrogon for the Treatment of Japanese Children with Growth Hormone Deficiency
https://t.co/aCfO23iJYQ

#daytrade #daytrading #stocks #stockmarketnews #stockstowatch